BACTELIDE
AXP000238.1 · Phage therapy
- Platform
- phage-loaded microcapsule spray
- Originator
- Precisio Biotix Therapeutics
- Sponsor
- Precisio Biotix Therapeutics
Names
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- bacteriophage cocktail against S. aureus, P. aeruginosa and K. pneumoniae
- Replication
- replicating
- Route
- topical
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04815798 | Phage Therapy for the Prevention and Treatment of Pressure Ulcers. | Unknown | Phase 1/2 | 2022-01 | 2023-08 | 69 | Pressure Ulcer |
Recent changes
No changes recorded in its trials yet.
Notes
Bacteriophage-loaded microcapsule spray for colonised pressure injuries (S. aureus, P. aeruginosa, K. pneumoniae); phase 1/2a NCT04815798. The registration also calls it PL-03-BM.
How to cite
BACTELIDE (AXP000238.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000238.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.